Get the Stockscreener App
191.20
1.17%
2.21
After Hours:
191.20
Biogen Inc stock is traded at $191.20, with a volume of 996.84K.
It is up +1.17% in the last 24 hours and up +1.91% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$188.99
Open:
$188.35
24h Volume:
996.84K
Relative Volume:
0.51
Market Cap:
$28.06B
Revenue:
$9.69B
Net Income/Loss:
$1.61B
P/E Ratio:
17.44
EPS:
10.9652
Net Cash Flow:
$2.26B
1W Performance:
+3.10%
1M Performance:
+1.91%
6M Performance:
+49.37%
1Y Performance:
+37.17%
1-Day Range:
$187.20
$192.00
1-Week Range:
$184.54
$202.41
52-Week Range:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
191.20 | 27.74B | 9.69B | 1.61B | 2.26B | 10.97 |
|
LLY
Lilly Eli Co
|
1,015.21 | 917.39B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
240.86 | 574.26B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
220.89 | 393.14B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.76 | 299.82B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
NVS
Novartis Ag Adr
|
160.06 | 301.87B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen (BIIB) Valuation Check After Q4 Beat And Momentum In New Drugs Like Leqembi - simplywall.st
FMR LLC's Strategic Acquisition of Biogen Inc Shares - GuruFocus
Biogen Inc. (BIIB) Announces Leadership Transition in Board of D - GuruFocus
Biogen Beats Pharmacies' MS Drug Monopoly Suit, For Now - Law360
Biogen (BIIB) Appoints Maria Freire as Upcoming Chair of Board - GuruFocus
Biogen Announces Board Chair Caroline Dorsa to Step Down - TipRanks
Biogen Announces Board Chair Transition - Biogen
Biogen (NASDAQ:BIIB) Price Target Raised to $236.00 - MarketBeat
Biogen Is Repositioning Its Portfolio to Partly Offset Ongoing Revenue Declines - Morningstar
Trading Systems Reacting to (BIIB) Volatility - Stock Traders Daily
Biogen (NASDAQ:BIIB) Insider Priya Singhal Sells 2,660 Shares - MarketBeat
Biogen Inc (BIIB) Insider Priya Singhal Sells 2,660 Shares - GuruFocus
Key facts: Biogen's LEQEMBI gets Priority Review in China; Wedbush raises price target - TradingView
BIIB: Wedbush Raises Price Target to $187 While Maintaining Neut - GuruFocus
Mizuho Raises Price Target on Biogen to $236 From $207, Keeps Outperform Rating - marketscreener.com
Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook - Yahoo Finance
State of Michigan Retirement System Has $6.04 Million Position in Biogen Inc. $BIIB - MarketBeat
Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next - Yahoo Finance
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China - ACN Newswire
Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point - simplywall.st
Analyst JP Morgan Raises Price Target for Biogen (BIIB) to $230 - GuruFocus
Biogen (BIIB) Sees Raised Price Target by Canaccord Genuity | BI - GuruFocus
Key facts: Analysts Boost Biogen Price Targets; Profit Outlook Improves; Leqembi Review Accelerated - TradingView
BIIB: BMO Capital Elevates Price Target While Maintaining Market Perform Rating | BIIB Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Centene (CNC) and Biogen (BIIB) - The Globe and Mail
Biogen (BIIB) Analyst Rating Update: Citigroup Raises Price Targ - GuruFocus
BIIB Analysts Maintain Rating, Significant Price Target Increase by TD Cowen | BIIB Stock News - GuruFocus
Biogen (NASDAQ:BIIB) Price Target Raised to $215.00 - MarketBeat
Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says - marketscreener.com
Guggenheim Raises Price Target on Biogen (BIIB) to $246 | BIIB S - GuruFocus
Goldman Sachs reiterates Buy rating on Biogen stock amid Leqembi growth - Investing.com
BMO Capital raises Biogen stock price target to $196 on Spinraza potential - Investing.com
BIIB: RBC Capital Increases Biogen's Price Target to $233 on Sus - GuruFocus
Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification' - Benzinga
Piper Sandler Raises Price Target for Biogen (BIIB) to $177 | BI - GuruFocus
Wells Fargo Raises Biogen (BIIB) Price Target to $200 | BIIB Sto - GuruFocus
Truist Securities Raises Price Target for Biogen (BIIB) to $193 | BIIB Stock News - GuruFocus
Biogen stock price target raised to $215 from $175 at TD Cowen - Investing.com
Biogen stock price target raised to $233 from $217 at RBC Capital - Investing.com
Piper Sandler raises Biogen stock price target to $177 on Leqembi ramp - Investing.com
Biogen’s much anticipated Tau readout in Alzheimer’s will spur more questions - PharmaLive
BIIB Stock Receives Raised Price Target from HC Wainwright & Co. - GuruFocus
Wedbush Raises Price Target on Biogen to $187 From $178, Keeps Neutral Rating - marketscreener.com
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
Guggenheim raises Biogen stock price target to $246 on pipeline potential - Investing.com
Canaccord Genuity raises Biogen stock price target on strong Q4 results - Investing.com
Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
RBC Raises Price Target on Biogen to $233 From $217, Keeps Outperform Rating - marketscreener.com
Biogen stock price target raised to $228 from $194 at H.C. Wainwright - Investing.com
Morgan Stanley Raises Price Target on Biogen to $190 From $156, Keeps Equalweight Rating - marketscreener.com
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):